Merck & Company (MRK) 63.24 $MRK The 7th Annual
Post# of 273249
Posted On: 09/07/2016 3:21:56 AM
Merck & Company (MRK) 63.24 $MRK
The 7th Annual AscendNAAMBA Conference & Career Exposition to Take Place at New York Hilton Midtown, September 9-10, 2016
PRWeb - Tue Sep 06, 9:03AM CDT
AscendNAAMBA (National Association of Asian MBAs), Ascend's national non-profit organization for MBA/graduate students and professionals, is hosting its 7th Annual AscendNAAMBA Conference & Career Exposition at New York Hilton Midtown, September 9-10, 2016.
MRK: 63.24 (+0.26)
Merck Stops Development of Odanacatib for Osteoporosis
Zacks Equity Research - Zacks Investment Research - Mon Sep 05, 6:35AM CDT
Merck & Co., Inc. (MRK) announced that it is discontinuing the clinical development of its osteoporosis investigational therapy, odanacatib as its overall benefit-risk profile does not support filing or further development.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), MRK: 63.24 (+0.26), ANIK: 48.34 (+0.45)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 63.24 (+0.26), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), BMY: 56.96 (+0.61), NVS: 80.15 (+0.77)
Merck Provides Update on Odanacatib Development Program
BusinessWire - Fri Sep 02, 6:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck's investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use. Merck previously reported a numeric imbalance in adjudicated stroke events in the pivotal Phase 3 fracture outcomes study in postmenopausal women. The company has decided to discontinue development after an independent adjudication and analysis of major adverse cardiovascular events confirmed an increased risk of stroke. The data from the analysis will be presented at the American Society for Bone Mineral Research (ASBMR) in September.
MRK: 63.24 (+0.26)
Global DNA Gyrase Subunit B (EC 5.99.1.3) Pipeline Review 2016 Featuring Abgentis, AstraZeneca, Daiichi Sankyo Company & Merck & Co. - Research and Markets
BusinessWire - Wed Aug 31, 7:43AM CDT
Research and Markets has announced the addition of the "DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1 2016" report to their offering.
MRK: 63.24 (+0.26)
Research and Markets - Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating the $150+ Billion Market
PR Newswire Europe - Wed Aug 31, 6:10AM CDT
DUBLIN, August 31, 2016 /PRNewswire/ --
MRK: 63.24 (+0.26), LLY: 78.51 (+1.66)
Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating
GlobeNewswire - Wed Aug 31, 3:16AM CDT
Research and Markets has announced the addition of the "Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment" report to their offering.
MRK: 63.24 (+0.26), LLY: 78.51 (+1.66)
Shares of MRK Up 20.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 30, 1:30AM CDT
SmarTrend identified an Uptrend for Merck (NYSE:MRK) on March 7th, 2016 at $52.34. In approximately 6 months, Merck has returned 20.39% as of today's recent price of $63.01.
MRK: 63.24 (+0.26)
Blog Coverage Consumer and Political Pressure Forces Mylan to Lower Cost of Epipen
ACCESSWIRE - Fri Aug 26, 8:19AM CDT
LONDON, UK / ACCESSWIRE / August 26, 2016 / Active Wall St. blog coverage looks at the headline from Mylan N.V. (NASDAQ: MYL). The company which has been facing tremendous public criticism and political backlash over the price increase for its product EpiPen announced on August, 25, 2016, that it is taking immediate action to enhance access by expanding existing programs to reach out to patients. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/
MRK: 63.24 (+0.26), MYL: 40.40 (+0.43)
Increasing R&D investments in Therapeutic Vaccines Market - Merck and GSK Have Interesting Pipelines
PR Newswire Europe - Fri Aug 26, 7:31AM CDT
HYDERABAD, India, August 26, 2016 /PRNewswire/ --
MRK: 63.24 (+0.26)
Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020 Featuring Bristol-Myers Squibb, Merck & Co & Navidea Biopharmaceuticals - Research and Markets
BusinessWire - Thu Aug 25, 12:55PM CDT
Research and Markets has announced the addition of the "Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020" report to their offering.
NAVB: 0.80 (+0.46), MRK: 63.24 (+0.26), BMY: 56.96 (+0.61)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 46.00 (+0.20), MRK: 63.24 (+0.26), AMGN: 170.84 (+1.07), LLY: 78.51 (+1.66), GSK: 43.99 (-0.27)
Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications
BusinessWire - Wed Aug 24, 10:25AM CDT
--Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans to initiate a Phase 1b/2 Imprime PGG/KEYTRUDA trial in patients with non-small cell lung cancer (NSCLC)
MRK: 63.24 (+0.26)
Research and Markets - Prophylactic Human Vaccines Market, 2022: Global Strategic Business Report 2016 - Leading Players are GlaxoSmithKline, Merck, Pfizer and Sanofi
PR Newswire Europe - Wed Aug 24, 7:11AM CDT
DUBLIN, August 24, 2016 /PRNewswire/ --
MRK: 63.24 (+0.26)
Welly Merck Announces the Launch of Their Swiss-Designed, Modern Fashion Watch Collection That Breaks Down Cost Barriers Between Makers and Consumers
PR Newswire - Tue Aug 23, 1:54PM CDT
Welly Merck, a boutique watch maker, announces the launch of their stunning new line of timepieces. Building on long family heritages in watchmaking and steel fabrication, Welly Merck represents a modern union of quality and fashion that makes luxury watches affordable for anyone.
MRK: 63.24 (+0.26)
Veterinary Vaccines Market is Expected to Rise to US$11,403.6 mn by 2024; Rising Expenditure on Animal Healthcare by Pet Owners and Livestock Farmers to Drive Market Globally, Reports TMR
PR Newswire Europe - Tue Aug 23, 6:31AM CDT
ALBANY, New York, August 23, 2016 /PRNewswire/ --
ZTS: 51.29 (+0.03), MRK: 63.24 (+0.26)
The 7th Annual AscendNAAMBA Conference & Career Exposition to Take Place at New York Hilton Midtown, September 9-10, 2016
PRWeb - Tue Sep 06, 9:03AM CDT
AscendNAAMBA (National Association of Asian MBAs), Ascend's national non-profit organization for MBA/graduate students and professionals, is hosting its 7th Annual AscendNAAMBA Conference & Career Exposition at New York Hilton Midtown, September 9-10, 2016.
MRK: 63.24 (+0.26)
Merck Stops Development of Odanacatib for Osteoporosis
Zacks Equity Research - Zacks Investment Research - Mon Sep 05, 6:35AM CDT
Merck & Co., Inc. (MRK) announced that it is discontinuing the clinical development of its osteoporosis investigational therapy, odanacatib as its overall benefit-risk profile does not support filing or further development.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), MRK: 63.24 (+0.26), ANIK: 48.34 (+0.45)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 63.24 (+0.26), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), BMY: 56.96 (+0.61), NVS: 80.15 (+0.77)
Merck Provides Update on Odanacatib Development Program
BusinessWire - Fri Sep 02, 6:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck's investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use. Merck previously reported a numeric imbalance in adjudicated stroke events in the pivotal Phase 3 fracture outcomes study in postmenopausal women. The company has decided to discontinue development after an independent adjudication and analysis of major adverse cardiovascular events confirmed an increased risk of stroke. The data from the analysis will be presented at the American Society for Bone Mineral Research (ASBMR) in September.
MRK: 63.24 (+0.26)
Global DNA Gyrase Subunit B (EC 5.99.1.3) Pipeline Review 2016 Featuring Abgentis, AstraZeneca, Daiichi Sankyo Company & Merck & Co. - Research and Markets
BusinessWire - Wed Aug 31, 7:43AM CDT
Research and Markets has announced the addition of the "DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1 2016" report to their offering.
MRK: 63.24 (+0.26)
Research and Markets - Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating the $150+ Billion Market
PR Newswire Europe - Wed Aug 31, 6:10AM CDT
DUBLIN, August 31, 2016 /PRNewswire/ --
MRK: 63.24 (+0.26), LLY: 78.51 (+1.66)
Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating
GlobeNewswire - Wed Aug 31, 3:16AM CDT
Research and Markets has announced the addition of the "Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment" report to their offering.
MRK: 63.24 (+0.26), LLY: 78.51 (+1.66)
Shares of MRK Up 20.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 30, 1:30AM CDT
SmarTrend identified an Uptrend for Merck (NYSE:MRK) on March 7th, 2016 at $52.34. In approximately 6 months, Merck has returned 20.39% as of today's recent price of $63.01.
MRK: 63.24 (+0.26)
Blog Coverage Consumer and Political Pressure Forces Mylan to Lower Cost of Epipen
ACCESSWIRE - Fri Aug 26, 8:19AM CDT
LONDON, UK / ACCESSWIRE / August 26, 2016 / Active Wall St. blog coverage looks at the headline from Mylan N.V. (NASDAQ: MYL). The company which has been facing tremendous public criticism and political backlash over the price increase for its product EpiPen announced on August, 25, 2016, that it is taking immediate action to enhance access by expanding existing programs to reach out to patients. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/
MRK: 63.24 (+0.26), MYL: 40.40 (+0.43)
Increasing R&D investments in Therapeutic Vaccines Market - Merck and GSK Have Interesting Pipelines
PR Newswire Europe - Fri Aug 26, 7:31AM CDT
HYDERABAD, India, August 26, 2016 /PRNewswire/ --
MRK: 63.24 (+0.26)
Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020 Featuring Bristol-Myers Squibb, Merck & Co & Navidea Biopharmaceuticals - Research and Markets
BusinessWire - Thu Aug 25, 12:55PM CDT
Research and Markets has announced the addition of the "Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020" report to their offering.
NAVB: 0.80 (+0.46), MRK: 63.24 (+0.26), BMY: 56.96 (+0.61)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 46.00 (+0.20), MRK: 63.24 (+0.26), AMGN: 170.84 (+1.07), LLY: 78.51 (+1.66), GSK: 43.99 (-0.27)
Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications
BusinessWire - Wed Aug 24, 10:25AM CDT
--Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans to initiate a Phase 1b/2 Imprime PGG/KEYTRUDA trial in patients with non-small cell lung cancer (NSCLC)
MRK: 63.24 (+0.26)
Research and Markets - Prophylactic Human Vaccines Market, 2022: Global Strategic Business Report 2016 - Leading Players are GlaxoSmithKline, Merck, Pfizer and Sanofi
PR Newswire Europe - Wed Aug 24, 7:11AM CDT
DUBLIN, August 24, 2016 /PRNewswire/ --
MRK: 63.24 (+0.26)
Welly Merck Announces the Launch of Their Swiss-Designed, Modern Fashion Watch Collection That Breaks Down Cost Barriers Between Makers and Consumers
PR Newswire - Tue Aug 23, 1:54PM CDT
Welly Merck, a boutique watch maker, announces the launch of their stunning new line of timepieces. Building on long family heritages in watchmaking and steel fabrication, Welly Merck represents a modern union of quality and fashion that makes luxury watches affordable for anyone.
MRK: 63.24 (+0.26)
Veterinary Vaccines Market is Expected to Rise to US$11,403.6 mn by 2024; Rising Expenditure on Animal Healthcare by Pet Owners and Livestock Farmers to Drive Market Globally, Reports TMR
PR Newswire Europe - Tue Aug 23, 6:31AM CDT
ALBANY, New York, August 23, 2016 /PRNewswire/ --
ZTS: 51.29 (+0.03), MRK: 63.24 (+0.26)
(0)
(0)Scroll down for more posts ▼